Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of ACT500 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Complicated With Chronic Hepatitis B
Clinical trial NCT07589400 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07589400
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2026-05-30
- Primary completion
- 2027-03-30
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.